{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:01:21Z","timestamp":1777680081293,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.<\/jats:p>","DOI":"10.1310\/hpj5201-27","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T16:39:53Z","timestamp":1485535193000},"page":"27-32","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma"],"prefix":"10.1177","volume":"52","author":[{"given":"Alexandra P.","family":"Punke","sequence":"first","affiliation":[{"name":"Blount Memorial Hospital, Maryville, Tennessee."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Aubrey","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Dominic A.","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"issue":"25","key":"bibr1-hpj5201-27","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel M.","year":"2014","journal-title":"J Clin Oncol."},{"key":"bibr2-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517276"},{"key":"bibr3-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.719614"},{"key":"bibr4-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"bibr5-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.175"},{"key":"bibr6-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"bibr7-hpj5201-27","doi-asserted-by":"crossref","unstructured":"JacobusS.J., RajkumarS.V., WeissM. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-dexamthasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen [letter]. Blood. 2016. http:\/\/www.nature.com\/bcj\/journal\/v6\/n7\/full\/bcj201655a.html. Accessed August 1, 2016.","DOI":"10.1038\/bcj.2016.55"},{"key":"bibr8-hpj5201-27","doi-asserted-by":"crossref","unstructured":"DurieB., HoeringA., RajkumarS.V. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in Patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): Results of the randomized phase III trial SWOG S0777. Blood. 2015 (abstract 25). http:\/\/www.bloodjournal.org\/content\/126\/23\/25?sso-checked=true. Accessed August 1, 2016.","DOI":"10.1182\/blood.V126.23.25.25"},{"key":"bibr9-hpj5201-27","unstructured":"National Cancer Comprehensive Network. NCCN Clinical Practice Guidelines \u2013 Multiple Myeloma. V.1.2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed October 11, 2016."},{"key":"bibr10-hpj5201-27","unstructured":"Bortezomib [package insert], Cambridge, MA: Millennium Pharmaceuticals, Inc; 2015. http:\/\/www.velcade.com\/fles\/pdfs\/velcade_prescribing_information.pdf. Accessed August 11, 2016."},{"key":"bibr11-hpj5201-27","unstructured":"National Cancer Comprehensive Network. NCCN Clinical Practice Guidelines \u2013 Antiemesis. V.2.2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed August 10, 2016."},{"key":"bibr12-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.4614"},{"key":"bibr13-hpj5201-27","unstructured":"National Cancer Comprehensive Network. NCCN Clinical Practice Guidelines \u2013 Myeloid Growth Factors. V.2.2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloid_growth.pdf. Accessed August 11, 2016."},{"key":"bibr14-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"bibr15-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6844"},{"key":"bibr16-hpj5201-27","unstructured":"National Cancer Comprehensive Network. NCCN Clinical Practice Guidelines \u2013 Cancer-Associated Venous Thrombo-embolic Disease. V.1.2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf. Accessed September 15, 2016."},{"key":"bibr17-hpj5201-27","unstructured":"Lenalidomide [package insert]. Summit, NJ: Celgene Corporation; 2015. http:\/\/www.revlimid.com\/wp-content\/uploads\/full-prescribing-information.pdf. Accessed August 11, 2016."},{"key":"bibr18-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007309563"},{"key":"bibr19-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20888"},{"key":"bibr20-hpj5201-27","volume-title":"Drug Prescribing in Renal Failure.","author":"Aronoff G.R.","year":"2007","edition":"5"},{"key":"bibr21-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2873"},{"key":"bibr22-hpj5201-27","unstructured":"Dexamethasone [package insert]. Roxane Laboratories, Inc.; 2015. http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Roxane\/Dexamethasone\/Dexamethasone%20Tablets%20Solution%20and%20Intensol.pdf. Accessed August 11, 2016."},{"key":"bibr23-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"bibr24-hpj5201-27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5201-27","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1310\/hpj5201-27","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5201-27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:34:25Z","timestamp":1777451665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1310\/hpj5201-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1310\/hpj5201-27"],"URL":"https:\/\/doi.org\/10.1310\/hpj5201-27","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}